LT3006454T - Nauji junginiai, turintys trigubą trombolitinį, prieštrombinį ir radikalų gaudyklės aktyvumą, bei jų sintezė, nanostruktūra ir naudojimas - Google Patents

Nauji junginiai, turintys trigubą trombolitinį, prieštrombinį ir radikalų gaudyklės aktyvumą, bei jų sintezė, nanostruktūra ir naudojimas

Info

Publication number
LT3006454T
LT3006454T LTEP14807973.4T LT14807973T LT3006454T LT 3006454 T LT3006454 T LT 3006454T LT 14807973 T LT14807973 T LT 14807973T LT 3006454 T LT3006454 T LT 3006454T
Authority
LT
Lithuania
Prior art keywords
thrombolysis
antithrombotic
nano
synthesis
new compounds
Prior art date
Application number
LTEP14807973.4T
Other languages
English (en)
Inventor
Shiqi Peng
Ming Zhao
Jianhui Wu
Yuji Wang
Qiqi FENG
Original Assignee
Shanghai Lumosa Therapeutics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Lumosa Therapeutics Co., Ltd. filed Critical Shanghai Lumosa Therapeutics Co., Ltd.
Publication of LT3006454T publication Critical patent/LT3006454T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP14807973.4T 2013-06-05 2014-06-03 Nauji junginiai, turintys trigubą trombolitinį, prieštrombinį ir radikalų gaudyklės aktyvumą, bei jų sintezė, nanostruktūra ir naudojimas LT3006454T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310225330 2013-06-05
PCT/CN2014/079098 WO2014194809A1 (zh) 2013-06-05 2014-06-03 具有溶栓、抗栓和自由基清除三重活性的新型化合物、其合成、纳米结构和应用

Publications (1)

Publication Number Publication Date
LT3006454T true LT3006454T (lt) 2021-04-12

Family

ID=52007559

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14807973.4T LT3006454T (lt) 2013-06-05 2014-06-03 Nauji junginiai, turintys trigubą trombolitinį, prieštrombinį ir radikalų gaudyklės aktyvumą, bei jų sintezė, nanostruktūra ir naudojimas

Country Status (24)

Country Link
US (5) US9890193B2 (lt)
EP (1) EP3006454B1 (lt)
JP (1) JP6510500B2 (lt)
KR (1) KR102204781B1 (lt)
CN (1) CN104231046B (lt)
AU (1) AU2014277416B2 (lt)
BR (1) BR112015027164B1 (lt)
CA (1) CA2914004C (lt)
CY (1) CY1123976T1 (lt)
DK (1) DK3006454T3 (lt)
ES (1) ES2847934T3 (lt)
HR (1) HRP20210566T1 (lt)
HU (1) HUE053351T2 (lt)
LT (1) LT3006454T (lt)
MX (1) MX362902B (lt)
PH (1) PH12015502684B1 (lt)
PL (1) PL3006454T3 (lt)
PT (1) PT3006454T (lt)
RS (1) RS61606B1 (lt)
RU (1) RU2660901C2 (lt)
SI (1) SI3006454T1 (lt)
TW (1) TWI633889B (lt)
WO (1) WO2014194809A1 (lt)
ZA (1) ZA201507237B (lt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106608905B (zh) * 2015-10-22 2020-10-16 彭莉 四氢异喹啉-3-甲酰-k(grpak)rgdv,其合成,活性及应用
CN106608902A (zh) * 2015-10-22 2017-05-03 彭莉 二羟基二甲基四氢异喹啉-3-甲酰-Lys(Lys),其合成,活性及应用
JP6663774B2 (ja) 2016-03-30 2020-03-13 東京エレクトロン株式会社 基板搬送方法及び基板処理システム
US11338008B2 (en) * 2019-09-25 2022-05-24 Lumosa Therapeutics Co., Ltd Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
KR20230041966A (ko) * 2020-05-15 2023-03-27 신헬릭스 펩티드 스캐폴드, 이를 제조하기 위한 방법, 및 가용성 지지체로서의 이의 용도
EP4313104A1 (en) 2021-03-22 2024-02-07 Lumosa Therapeutics Co., Ltd. Dc009 for treating acute ischemic stroke
CN115403653B (zh) * 2022-05-19 2024-08-06 首都医科大学 D(+)-β-(3,4-二羟基苯基)-乳酰-Pro-Ala-Lys,其合成及应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5222632B2 (lt) * 1972-08-22 1977-06-18
JP2004523530A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
EP1469851B1 (en) 2002-01-23 2006-10-11 Eli Lilly And Company Melanocortin receptor agonists
CA2508891A1 (en) * 2002-12-23 2004-07-22 Janssen Pharmaceutica, N.V. Heteroaryl peptidomimetics as thrombin receptor antagonists
CN101190895B (zh) 2006-11-30 2010-05-26 首都医科大学 N-[(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸、其制备方法及应用
CN101190941B (zh) * 2006-11-30 2010-12-01 首都医科大学 具有溶血栓活性的多肽、其制备方法及应用
CN101200493B (zh) 2006-12-11 2011-11-09 首都医科大学 (3s)-n-(l-氨基酰)-1,2,3,4-四氢异喹啉-3-羧酸、其制备方法及应用
CN102241740B (zh) * 2008-01-30 2014-02-19 首都医科大学 具有溶血栓活性的化合物、其制备方法、其应用
CN101497651B (zh) * 2008-01-30 2012-06-27 首都医科大学 具有溶血栓活性的化合物、其制备方法、其应用
CN101899084B (zh) 2009-05-26 2012-09-05 首都医科大学 (3s)-1,2,3,4-四氢异喹啉-3-羧酸三肽缀合物及其制备方法和应用
CN102120727B (zh) 2010-01-07 2013-08-28 首都医科大学 N-[(3s)-n-氨基酰-1,2,3,4-四氢异喹啉-3-甲酰基]氨基酸及其合成方法和应用
CN102127097A (zh) 2010-01-15 2011-07-20 首都医科大学 N-(3s-1,2,3,4-四氢异喹啉-3-甲酰基)氨基酸铜络合物及其制备方法和应用
CN102477068B (zh) 2010-11-30 2013-07-24 首都医科大学 用于制备溶血栓药物的氨基酸衍生物及其制备方法和应用
TWI586651B (zh) * 2011-10-14 2017-06-11 必治妥美雅史谷比公司 作為因子xia抑制劑之經取代四氫異喹啉化合物
CN103145797B (zh) 2011-12-07 2015-05-20 首都医科大学 [(3s)-1,2,3,4-四氢异喹啉-3-甲酰基]-Lys修饰的RGD四肽,其合成和在医学中的应用
CN103450338B (zh) 2012-05-29 2016-08-24 首都医科大学 杂环羧酸修饰的胸腺五肽,其制备,抗肿瘤作用和应用
CN103450330B (zh) * 2012-06-01 2016-05-25 首都医科大学 二羟基四氢异喹啉-3-甲酰氨基酸、其合成、抗血栓作用和应用
TWI568747B (zh) * 2012-09-05 2017-02-01 上海晟順生物科技有限公司 同時具溶血栓、清除自由基和血栓靶向功能的新穎化合物及其製備方法和用途
CN102887941A (zh) * 2012-09-05 2013-01-23 永光制药有限公司 Pak/咪唑啉/rgd三元缀合物及其制备方法和用途

Also Published As

Publication number Publication date
US9890193B2 (en) 2018-02-13
CY1123976T1 (el) 2022-05-27
RU2660901C2 (ru) 2018-07-11
TW201521759A (zh) 2015-06-16
PT3006454T (pt) 2021-01-29
EP3006454B1 (en) 2021-01-13
ES2847934T3 (es) 2021-08-04
US20200055895A1 (en) 2020-02-20
CN104231046A (zh) 2014-12-24
US10351594B2 (en) 2019-07-16
MX2015015924A (es) 2016-04-06
PH12015502684A1 (en) 2016-03-07
HRP20210566T1 (hr) 2021-06-25
KR20160016863A (ko) 2016-02-15
MX362902B (es) 2019-02-22
BR112015027164B1 (pt) 2023-03-21
WO2014194809A1 (zh) 2014-12-11
JP2016521696A (ja) 2016-07-25
KR102204781B1 (ko) 2021-01-20
US20230312644A1 (en) 2023-10-05
AU2014277416A1 (en) 2015-12-24
AU2014277416B2 (en) 2018-02-22
PL3006454T3 (pl) 2021-06-28
US20210355163A1 (en) 2021-11-18
SI3006454T1 (sl) 2021-04-30
RS61606B1 (sr) 2021-04-29
EP3006454A4 (en) 2016-11-30
US20160083423A1 (en) 2016-03-24
TWI633889B (zh) 2018-09-01
CA2914004A1 (en) 2014-12-11
CN104231046B (zh) 2017-05-03
ZA201507237B (en) 2019-11-27
PH12015502684B1 (en) 2016-03-07
CA2914004C (en) 2022-01-25
EP3006454A1 (en) 2016-04-13
HUE053351T2 (hu) 2021-06-28
JP6510500B2 (ja) 2019-05-08
US20180134748A1 (en) 2018-05-17
RU2015147247A (ru) 2017-05-05
DK3006454T3 (da) 2021-04-12
BR112015027164A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
IL267758B (en) Endophyte populations of seed origin, preparations and methods of use
HRP20170888T1 (hr) Spoj tubulisina, metode pripreme i primjena
IL245184A0 (en) Prostacyclin compounds, preparations and methods of using them
ZA201507237B (en) New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
SG11201601047SA (en) Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
EP3054974A4 (en) Glycan-interacting compounds and methods of use
EP3004289A4 (en) Treatment of coal
IL244066A0 (en) Triazolopyridine compounds, preparations and methods for their use
HK1213151A1 (zh) 葉黃素組合物及使用方法
HK1224327A1 (zh) 插層漂白劑組合物、製造和使用的相關方法
HK1223640A1 (zh) 插層漂白劑組合物、製造和使用的相關方法
EP3090742A4 (en) Use of compounds produced from arrabidaea brachypoda extracts as anti-ulcerogenic agents
GB2525530B (en) Treatment of hard surfaces
AU2013900781A0 (en) Nacre-like composites, methods of synthesis and methods of use
TWM475269U (en) The mechanisms of curette lighting